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Abstract
Background: Vimentin is one of the cytoplasmic intermediate filament proteins which are the
major component of the cytoskeleton. In our study we checked the usefulness of vimentin
expression in identifying cases of breast cancer with poorer prognosis, by adding vimentin to the
immunopanel consisting of basal type cytokeratins, estrogen, progesterone, and HER2 receptors.
Methods: 179 tissue specimens of invasive operable ductal breast cancer were assessed by the use
of immunohistochemistry. The median follow-up period for censored cases was 90 months.
Results: 38 cases (21.2%) were identified as being vimentin-positive. Vimentin-positive tumours
affected younger women (p = 0.024), usually lacked estrogen and progesterone receptor (p <
0.001), more often expressed basal cytokeratins (<0.001), and were high-grade cancers (p < 0.001).
Survival analysis showed that vimentin did not help to delineate basal type phenotype in a triple
negative (ER, PgR, HER2-negative) group. For patients with 'vimentin or CK5/6, 14, 17-positive'
tumours, 5-year estimated survival rate was 78.6%, whereas for patients with 'vimentin, or CK5/6,
14, 17-negative' tumours it was 58.3% (log-rank p = 0.227).
Conclusion: We were not able to better delineate an immunohistochemical definition of basal
type of breast cancer by adding vimentin to the immunopanel consisted of ER, PgR, HER2, CK5/6,
14 and 17 markers, when overall survival was a primary end-point.
Background
Vimentin is a 57 kDa intermediate filament (IF) protein,
which forms a part of the cytoskeleton. Six major classes
of IFs are believed to be relatively specific for certain cell
types, for example keratin in epithelial cells, neurofila-
ments in neurons, glial fibrillary acid protein in glial cells,
desmin in muscule cells and vimentin in mesenchymal
cells. Obviously, they are variably expressed in different
cell types and in corresponding tumours. Expression of
vimentin and cytokeratins has also been described in
breast carcinomas [1,2].
Moreover, vimentin is selectively expressed in aggressive
breast cancer cell lines [3]. Elevated vimentin expression
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level correlates well with up-regulated migration and
invasion of cancer cells [3,4]. The transfection of the non-
invasive human breast cancer cell line (MCF7) with
vimentin gene led to accelerated invasiveness [5]. Other
data showed that more invasive breast cancer lines
expressed vimentin, suggesting its usefulness in identify-
ing cases with poorer prognosis [6].
Vimentin reactive cells in benign and malignant breast tis-
sue have been described by many authors [4,7]. The same
applies to a possible association with clinically aggressive
behavior of tumours [7], which may be explained by cor-
relation with estrogen receptor negativity [8,9], high Ki-67
level [9] and poor differentiation of tumours (high grade)
[10,11].
Few reports are in opposite, as they showed that vimentin
expression did not inversely predict patient survival [12].
The cDNA microrray experiments enabled the identifica-
tion of different subgroups of breast tumours with distinct
molecular signatures [13-15]. This molecular classifica-
tion delineated at least four biologically different pheno-
types: luminal phenotype (generally, estrogen receptor
positive tumours), normal breast-like phenotype and
estrogen receptor negative tumours, comprising the sub-
groups of HER2 (overexpression of ERBB2 oncogene) and
basal-like phenotypes (tumours expressing genetic mark-
ers that are characteristic of the myoepithelium of the nor-
mal mammary gland, such as epidermal growth factor
receptor, p63 and basal cytokeratins CK 5/6, CK 14, CK17
[13-15]. It is also known that a subgroup with HER 2 over-
expression and basal-like phenotype correlate with poor
prognosis. Many efforts have been undertaken to repro-
duce this classification with the use of immunohisto-
chemistry instead of assessment of mRNA [16-18].
Some researchers suggested that immunohistochemically
triple negative tumours (ER, PgR, and HER 2-negativity)
could reliably be defined as basal-like tumours, making
these two subgroups synonymous [19]. Others believe
that equating triple negative tumours with basal-like
breast cancer is misleading [20]. However, there is a com-
mon agreement that the key point of basal-like character-
istics is triple negativity of tumours. On the other hand, it
should be stressed that not only basal-like cancers har-
bour a triple negative phenotype at the mRNA level, and
normal-breast like cancers also have this feature [13,21].
It has been shown that typical features of basal-like
tumours include the expression of: high molecular weight
cytokeratins – CK5/6, 14, 17 (so-called basal type cytok-
eratins) [18,22,23], expression of epidermal growth factor
receptor (EGFR), c-kit, P53, and vimentin
[4,16,18,20,23,24].
Recent studies have compared the prognostic significance
of three-(ER, PgR, HER2) and five-biomarker (ER, PgR,
HER2, CK5/6, EGFR) surrogate panels to define intrinsic
breast cancer subtypes and have suggested that the
extended immunopanel provided more specific defini-
tion of basal like breast cancer, which can better predict
survival of breast cancer patients [25].
The aim of our study was to assess if the immunopanel
consisted of triple negative phenotype (ER, PgR, HER2)
with the addition of basal cytokeratins (CK5/6, 14, 17) or
vimentin could better delineate a basal type tumour group
and better predict patient survival when compared to only
pure ER, PgR, HER2 negative phenotype.
Materials and methods
A series of 179 formalin fixed, paraffin-embedded inva-
sive ductal carcinomas not otherwise specified were
acquired from the archives of the Pathology Department
of Copernicus Memorial Hospital, Lodz, Poland. Patients
had undergone surgery (total mastectomy with axillary
lymph node dissection) between 1997 and 2001. The
median patient age at surgery was 56 years (range, 25–92
years).
The primary pathologic diagnosis was confirmed in H&E
staining. All operative and pathologic reports were
reviewed to confirm disease stage. Follow-up period was
defined as a time from surgery to the last observation for
censored cases or death for complete observations.
Immunohistochemistry and scoring
Sections of 2 μm thickness were cut and mounted onto
polylysine-coated slides, which were stained for vimentin,
estrogen receptor (ER), progesterone receptor (PgR),
HER2, cytokeratin 5/6, 14 and 17, Ki-67, cyclin E and p-
cadherin.
Staining procedures
Antibodies against:
- vimentin (Dako), dilution 1:50, antigen retrieval: auto-
clave, high pH;
- CK5/6 (Dako), 1:100, autoclave, high pH;
- CK 14 (Novocastra), 1:20, microwave oven, citrate
buffer, pH 6;
- CK17 (Novocastra), 1:40, microwave oven, citrate
buffer, pH 6;
- ER (Dako),1:35, microwave oven, citrate buffer, pH 6;Journal of Experimental & Clinical Cancer Research 2009, 28:118 http://www.jeccr.com/content/28/1/118
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- PgR (Dako),1:75, microwave oven, citrate buffer, pH 6;
- HER2 (Herceptest, Dako) and Ki-67 (Dako), 1:200,
microwave oven, citrate buffer, pH 6;
- cyclin E (Dako), 1:40, microwave oven, citrate buffer, pH
6;
- p-cadherin (Dako), 1:200, microwave oven, citrate
buffer, pH 6.
Scoring
Any distinct positive staining of tumour parenchyma with
vimentin antibody was regarded as vimentin expression.
Positive staining in fibroblasts, endothelial cells, lym-
phocytes and macrophages served as 'built-in' positive
control, furthermore, negative staining of epithelial cells
in non-neoplastic tubules served as negative control.
For CK5/6, CK14 and CK17, membranous staining results
were classified as follows: negative – no staining seen in
invasive tumour cells, positive – weak or strong staining
seen in invasive cancer cells.
ER and PgR nuclear staining scoring was done using the
method described by McCarty et al. [26]. Tumours were
considered as being positive for ER or PgR if Histo-score
was above 100.
HER2 staining was scored according to Herceptest kit
manufacturer's instructions and score 3+ denoted HER2-
positive tumours.
Ki-67 and cyclin E labeling indices were defined as the
percentages of tumour cells displaying nuclear immuno-
reactivity and were calculated by counting nuclear stained
tumour cells in 1000 tumour cells. For cyclin E, samples
were classified as being negative (<2%) or positive (≥ 2%).
For p-cadherin, a semiquantitative scoring system was
used, taking into account both the intensity of staining
and the proportion of tumour cells showing the positive
reaction. The scores of staining intensity were recorded
from 0 (no staining) to 3 (strong staining). The scores of
staining area were recorded as 1 (<10%), 2 (10–50%) or
3 (>50%). A staining index (SI) was obtained by multiply-
ing the score of staining intensity by the score of staining
area, negative cases had SI = 0–1, positive ones had SI = 2–
9.
Statistical analysis
Pearson's chi-square test or Fisher exact test were used to
test for contingency between dichotomized values of
vimentin expression (negative and positive) and values of
other histopathological and clinical parameters. Patient
survival was calculated from the date of primary surgery to
the date of death or the last follow-up according to the
Kaplan-Meier method. Data for patients who died from
other causes than breast cancer were censored at the time
of death. Differences in survival distributions were evalu-
ated by a log-rank test. Univariate survival analyses were
performed with the use of Cox proportional hazards
method. All results were considered statistically signifi-
cant when two-sided p was less than 0.05. The analyses
were performed using the StatsDirect software (StatsDirect
Ltd., UK).
Results
Patient characteristics and vimentin expression
The median follow-up period for all patients was 71
months (range, 1–130), and for 113 censored (living)
patients it was 90 months (range, 9–130).
Vimentin expression was observed in 38 cases (21.2%)
(Table 1, Fig. 1), whereas 141 (78.8%) (Table 1) tumours
were found to be vimentin-negative.
Women with vimentin-positive cancers were significantly
younger when compared with vimentin-negative ones
(Table 1).
Among 38 vimentin-positive tumours, 31 were ER-nega-
tive and 31 were PgR-negative, whereas 7 were ER and
PgR-positive (p < 0.001) (Table 1). Also 37 cases were
HER2-negative and only 1 was positive (p < 0.004) (Table
1). Moreover, vimentin expressing tumours were usually
positive for at least one of the basal type cytokeratins
(CK5/6 or CK14 or CK17) (p < 0.001) (Table 1).
Vimentin-positive tumours were significantly more often
high grade tumours. Such relationship was very strong in
all patients (p < 0.001) and significant in triple negative
tumours (p = 0.035). In the non-triple negative group
only not significant tendency towards such relationship
was observed (p = 0.065).
There was also a statistically insignificant but quite obvi-
ous tendency towards a relationship between vimentin
and cyclin E. Vimentin-positive tumours more frequently
expressed cyclin E (p = 0.058) (Table 1). Relation with Ki-
67 and p-cadherin did not attain statistical significance (p
= 0.152 and p = 0.110, respectively) (Table 1).
54 patients had triple negative tumours (30.2%) (Table
2), whereas non-triple negative phenotype defined as the
expression of at least one of the three markers (ER, PgR orJournal of Experimental & Clinical Cancer Research 2009, 28:118 http://www.jeccr.com/content/28/1/118
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Table 1: Associations between clinical and histopathological features and expression of vimentin.
Feature Vimentin-negative
N = 141
Vimentin-positive
N = 38
p value
Age (mean) 58.09 51.79 0.024
Tumour size 0.294
T1 43 15
T2-4 98 23
Nodal status 0.718
Negative 64 16
Positive 77 22
Grading <0.001
G1-2 90 10
G3 51 28
ER <0.001
Negative 70 31
Positive 71 7
PgR <0.001
Negative 64 31
Positive 77 7
CK5/6 <0.001
Negative 109 8
Positive 32 30
CK14 <0.001
Negative 134 21
Positive 7 17
CK17 <0.001
Negative 118 16
Positive 23 22
CK5/6 or 14 o r17 <0.001
Negative 105 8
Positive 36 30
HER2 0.004
Negative 110 37
Positive 31 1
Triple negativity <.001
Yes 25 29
No 116 9
P-cadherin 0.110
Negative 61 11
Positive 80 27
Cyclin E 0.058
Negative 65 11
Positive 76 27
Ki-67 expression, % (mean) 9.09 11.34 0.152
The second and third columns contain numbers of patients, age and Ki-67 expression excepted.Journal of Experimental & Clinical Cancer Research 2009, 28:118 http://www.jeccr.com/content/28/1/118
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HER2) was observed in 125 patients (69.8%) (Table 2).
Among 54 triple negative tumours, 39 (72.2%) were
'CK5/6 or 14 or 17'-positive and 15 (27.8%) were nega-
tive for these keratins. 'Vimentin or CK5/6 or 14 or 17'
positivity was established for 42 (77.8%), and negativity
for 12 (22.2%) triple negative tumours.
Survival analysis
All (n = 179) patients
As a single marker, vimentin was not associated signifi-
cantly with patient survival (hazard ratio 1.22, 95%CI
0.69–2.14, p = 0.497; log-rank p = 0.496) (Table 2). Also
compilation of basal cytokeratins (CK5/6 or CK14 or
CK17 – positive vs. negative tumours) was not associated
significantly with patient survival (hazard ratio 1.46,
95%CI 0.90–2.37, p = 0.127; log-rank p = 0.124) (Table
2, Fig. 2). However, adding vimentin to basal cytokeratins
compilation (vimentin or CK5/6 or CK14 or CK17-posi-
tive vs. negative tumours) could significantly determine
the prognosis (Table 2, Fig. 3).
Patients with triple negative tumours (n = 54)
In 54 (30.2%) triple negative patients vimentin as a single
marker did not predict clinical outcome (hazard ratio
0.64, 95%CI 0.28–1.48, p = 0.297; log-rank p = 0.293)
(Table 2).
There was a tendency towards slightly better outcome in
'CK5/6 or 14 or 17'-positive patients when compared with
the negative ones but this difference was not significant
(Table 2, Fig. 4). There was no significant difference in
clinical outcome between 'vimentin or CK5/6 or 14 or 17'
– positive vs. negative patients (Table 2, Fig. 5).
Patients with non-triple negative tumours (n = 125)
In a non-triple negative group only 9 patients were posi-
tive for vimentin. Thus, results of survival analysis shown
in Table 2 should be regarded as being inconclusive and
they are presented for comparative purposes only.
Discussion
In this study, positive staining for vimentin was found in
21.2% of cases, the proportion which is similar [9],
smaller [12] or higher [2] to reported by others. Such dis-
agreements between studies could be possibly explained
by the subjectivity of the method and differences between
scoring systems used. Some authors have pointed out that
differences in vimentin expression may depend on the
type of tissue fixation – the smaller amount of vimentin-
expressing cells is observed in formalin fixed, paraffin-
embedded tissues [27,28]. In our study, there was a statis-
tically significant correlation between vimentin expres-
sion and poor differentiation of tumours (G3 cancers)
both in all patients and in the triple negative group. In the
non-triple negative group, due to the limited number of
vimentin-positive tumours, only not significant, although
an obvious tendency towards such relationship was
observed. Our observations remain in concordance with
data published by others [10,29,30]. Also, vimentin
expressing tumours had slightly higher Ki-67 level, but
without statistical significance, so this particular result is
not supported by other analyses [4,9]. Published data
showed significant associations between basal keratins
expression (CK5/6, CK14) and vimentin expression [23].
In our study, a very strong (p < 0.001) association
between vimentin expression and expression of at least
one of the basal type cytokeratin (CK5/6 or CK14 or
CK17) was also confirmed. In the present study, vimen-
tin-positive cancers were more often found in younger
women. This result remains to some extent in contrast
with observations made by Chen at al. that vimentin and
basal cytokeratins were expressed at significantly lower
lewels in breast cancer cells from women aged 31 years
and below compared with those from patients between 32
and 35 years old [30]. However, Abd El-Rehim at al. and
Cheang at al. have found correlation between basal mark-
ers expression and younger patient age [18,25].
Univariate survival analysis, for all patients, showed that
vimentin expression did not influence the clinical out-
come, so we agree with some researchers who have shown
that vimentin positivity was not associated with any dif-
ference in patient survival [12,29]. Thus, we cannot sup-
port the hypothesis suggesting the usefulness of vimentin
as a single marker in identifying cases with poorer progno-
sis [9]. Only in the group of non-triple negative patients,
vimentin expression attains significance with survival of
Positive staining for vimentin Figure 1
Positive staining for vimentin. Breast cancer, magnifica-
tion × 100.Journal of Experimental & Clinical Cancer Research 2009, 28:118 http://www.jeccr.com/content/28/1/118
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patients (p = 0.005) but this group contains only 9 posi-
tive cases, so we consider this results as being inconclusive
and we have showed them for comparative purposes only.
In our study, an immunopanel containing 'vimentin-pos-
itive or basal cytokeratin (CK5/6, 14, 17)-positive and tri-
ple negative (ER, PGR, HER2)' markers was formulated
and its prognostic value has been checked out by the com-
parison with 'basal cytokeratin (CK5/6, 14, 17)-positive
and triple negative (ER, PGR, HER2)' panel, in which
vimentin is omitted.
These two basal phenotype immunopanels were adversely
associated with survival in patients with non-triple nega-
tive cancer (Table 2). This effect was far less evident in a
group of all patients – only a four-marker immunopanel
consisting of CK5/6, CK14, CK17 and vimentin was sig-
nificantly related to the clinical outcome. This can be
Table 2: Prognostic value of basal type breast cancer delineated by two different immunopanels.
Subgroup Hazard ratio (95%CI) p value 5-year survival rate (95%CI) (%) p value (log-rank)
All patients (n = 179)
'CK5/6 or 14 or 17' 1.46 (0.90–2.37) 0.127 0.124
Positive 63.5 (50.7–73.8)
Negative 75.3 (66.1–82.4)
Vimentin 1.22 (0.69–2.14) 0.497 0.496
Positive 59.5 (42.1–73.3)
Negative 73.9 (65.7–80.4)
'Vimentin or CK5/6 or 1.73 (1.07–2.81) 0.026 0.024
14 or 17'
Positive 61.5 (49.3–71.6)
Negative 77.6 (68.2–84.5)
Triple negative patients (n = 54)
'CK5/6 or 14 or 17' 0.50 (0.21–1.20) 0.122 0.115
Positive 71.8 (54.9–83.3)
Negative 52.5 (25.2–74.0)
Vimentin 0.64 (0.28–1.48) 0.297 0.293
Positive 69.0 (48.8–82.5)
Negative 68.0 (46.1–82.5)
'Vimentin or CK5/6 or 0.56 (0.22–1.45) 0.234 0.227
14 or 17'
Positive 78.6 (62.9–88.2)
Negative 58.3 (27.0–80.1)
Non-triple negative patients (n = 125)
'CK5/6 or 14 or 17' 2.61 (1.40–4.84) 0.002 0.002
Positive 50.9 (30.7–67.9)
Negative 77.8 (67.9–84.9)
Vimentin* 3.26 (1.37–7.77) 0.008 0.005
Positive 25.4 (3.8–56.4)
Negative 75.2 (66.1–82.2)
'Vimentin or CK5/6 or 3.04 (1.66–5.56) <0.001 <0.001
14 or 17'
Positive 47.5 (29.1–63.8)
Negative 80.1 (70.2–87.0)
*In a non-triple negative group only 9 patients were positive for vimentin. Thus, results of survival analysis should be regarded as being inconclusive 
and they are showed for comparative purposes only.Journal of Experimental & Clinical Cancer Research 2009, 28:118 http://www.jeccr.com/content/28/1/118
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explained at least partially by correlation of vimentin
expression with ER and PgR negativity, and with higher
grade of cancer. However, the main purpose of the present
study was to assess the prognostic usefulness of basal
markers including vimentin in a triple negative group. We
have found that in triple negative patients none of the
basal phenotype immunopanels was adversely related
with patients' survival. On the contrary, there was an
insignificant tendency towards better prognosis when
basal keratins or vimentin were detected in a primary
tumour. This observation remains to some extent in con-
trast with observations made by Cheang et al. [25], Liu et
al. [31], and by Rakha et al. [32]. However, Jumppanen et
al. have found that the clinical outcome of basal tumours
is similar to non-basal ER-negative tumours [33]. Moreo-
ver, they have observed that basal keratins expression sig-
nificantly affected survival only during the first 5 years of
follow-up and lost its significance later on. In our study
the median follow-up period in a group of surviving
patients was 7.5 years and our observation corresponds
Overall survival depending on the immunopanel ('CK5/6 or  14 or 17') used in the determination of basal type tumours Figure 2
Overall survival depending on the immunopanel 
('CK5/6 or 14 or 17') used in the determination of 
basal type tumours. All patients (n = 179).
p=0.124
Overall survival
0 50 100 150
0,00
0,25
0,50
0,75
1,00
CK5/6_14_17(+)
CK5/6_14_17(-)
Times
Overall survival depending on the immunopanel ('Vimentin  or CK5/6 or 14 or 17') used in the determination of basal  type tumours Figure 3
Overall survival depending on the immunopanel 
('Vimentin or CK5/6 or 14 or 17') used in the deter-
mination of basal type tumours. All patients (n = 179).
p=0.024
Overall survival
0 50 100 150
0,00
0,25
0,50
0,75
1,00
Vimentin_CK5/6_14_17(+)
Vimentin_CK5/6_14_17(-)
Times
Overall survival depending on the immunopanel ('CK5/6 or  14 or 17') used in the determination of basal type tumours Figure 4
Overall survival depending on the immunopanel 
('CK5/6 or 14 or 17') used in the determination of 
basal type tumours. Patients with triple negative cancer (n 
= 54).
p=0.115
Overall survival
0 50 100 150
0,00
0,25
0,50
0,75
1,00
CK5/6_14_17(+)
CK5/6_14_17(-)
Times
Overall survival depending on the immunopanel ('Vimentin  or CK5/6 or 14 or 17') used in the determination of basal  type tumours Figure 5
Overall survival depending on the immunopanel 
('Vimentin or CK5/6 or 14 or 17') used in the deter-
mination of basal type tumours. Patients with triple neg-
ative cancer (n = 54).
p=0.227
Overall survival
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well with observations made by Jumppanen and col-
leagues [33]. Indeed, Tischkowitz et al. have found that
the difference in survival rate between triple negative and
non-triple negative breast cancer is reduced with longer
follow-up period [34]. When basal phenotype markers
like CK 5/6 and HER1 (EGFR) were analyzed without con-
sideration of steroid receptors status, the reduction in sur-
vival of patients expressing these markers was more
pronounced at 10 years of observation that at 3 years. Our
results, although restricted by a relative small number of
patients with triple negative phenotype, confirm these
findings.
The present study also supports our previous analysis
which showed that basal cytokeratins (CK5/6 and CK17)
expression had not any impact on survival in patients with
breast cancer [35].
The possible association of vimentin with clinically
aggressive behaviour of tumours described by others [7-
9,11] may be explained by the correlation of vimentin
expression with lack of steroid receptors and poor differ-
entiation of cancer. We can confirm this observation
(Table 1).
However, we cannot offer a better indicator of basal type
breast cancers by adding vimentin to the diagnostic panel
when overall survival is a primary end-point. Also, an
immunopanel defined as CK5/6 or 14 or 17-positivity did
not show any significant prognostic value in survival anal-
ysis in a triple negative group. Five marker method pro-
posed by Cheang et al. [25] showed superior prognostic
value than only triple negative phenotype. In their analy-
sis, triple negative, CK5/6-positive and EGFR-positive
tumours were selected. Taken into consideration a strong
positive correlation between EGFR and vimentin expres-
sion [4], we have taken an effort to construct an immuno-
panel defining basal-type tumours as triple negative
tumours that are vimentin-positive or basal cytokeratin-
positive. In a comparison with Cheang's study, our analy-
sis was based on a smaller number of patients and instead
of EGFR, vimentin expression was applied. However, in
our study, the median follow-up period in a group of liv-
ing patients almost reached 8 years. To understand, why
the presence of vimentin or basal cytokeratins is not
related to triple negative patient outcome, further studies
should be undertaken.
Conclusion
In summary, may we conclude that adding vimentin to an
immunopanel consisted of basal cytokeratins (CK5/6, 14,
17) appears to be inefficient at predicting survival of triple
negative breast cancer patients.
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